Searching…
By blocking these enzymes, Kisqali slows or stops the growth of cancer cells. Kisqali is not chemotherapy, it is a targeted treatment. Kisqali is usually used in combination with hormone therapies, such as an aromatas...
Learn about KISQALI, a treatment option for HR+, HER2- early breast cancer (eBC) and metastatic breast cancer (mBC). See full Prescribing and Safety Info.
It can be used to treat breast cancer that is advanced or has spread to other parts of the body (metastatic). Kisqali is usually used in combination with another medicine to treat breast cancer....
Kisqali (ribociclib) is a CDK4/6 inhibitor used to treat certain cases of estrogen-receptor-positive, HER2-negative breast cancer.
Pre/perimenopausal women, or men, treated with the combination KISQALI plus an aromatase inhibitor or fulvestrant, should be treated with a luteinizing hormone-releasing hormone (LHRH) agonist according to current cli...
What is KISQALI? KISQALI is a prescription medicine used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that...
Ribociclib is a targeted or biological therapy drug. When used to treat breast cancer, ribociclib is taken alongside hormone (endocrine) therapy. Ribociclib is the drug’s non-branded name. Its brand name is Kisqali. I...
KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor...
Kisqali (ribociclib) is commonly used for treating breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative and is advanced or has spread...
Learn about cost, uses, and more for Kisqali (ribociclib), which is a prescription tablet that treats breast cancer in adults.
